Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer: An exploratory analysis of the Intergroup trial AGO-OVAR 12
Gynecologic Oncology Feb 02, 2019
Heitz F, et al. - Authors assessed 1,345 patients with advanced ovarian cancer (AOC) to find contributing factors for impaired survival in cases with completely resected AOC. They observed tumor in 28% and 22% of those undergoing radiologic and integrated assessment, respectively. They also noted 5-year overall survival (5Y-OS) of 72% and 71% among those with surgical- radiological and surgical-integrated concordant findings. An inferior 5Y-OS of 47% and 49% was also recorded for candidates with surgical-radiological and surgical-integrated discordant results. They noticed that cases with surgically assessed residual disease had a 5-YOS of 37%. An independent relationship was observed between the interval between surgery and baseline assessment and discordance between assessment methods, which might reflect early tumor regrowth.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries